Current Neuro-Oncology
Volume
24 Number 16
31 August 2022
Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 16, 31 August
Dissaux
B, Mazouz Fatmi D, Ognard J, Allard B, Keromnes N, Latreche A,
Lepeuve A, Schick U, Bourbonne V, Ben Salem D, Dissaux G,
Querellou S.
Radiotherapy
Target Volume Definition in Newly Diagnosed High-Grade Glioma
Using 18F-FET PET Imaging and Multiparametric MRI: An Inter
Observer Agreement Study.
Tomography.
2022 Aug 16;8(4):2030-2041∟.
doi: 10.3390/tomography8040170∟.
PMID: 36006068∟.
Interventional study. ˍ
Li
J, Yang W, Yuan Y, Zuo M, Li T, Wang Z, Liu Y.
Preoperative
Naples prognostic score is a reliable prognostic indicator for
newly diagnosed glioblastoma patients.
Front
Oncol. 2022 Aug 16;12:775430∟.
doi: 10.3389/fonc.2022.775430∟.
PMID: 36052263∟.
Observational study. ˍ
Shi
DD, Youssef GC, Nassar AH, Lim-Fat MJ, Ligon KL, Wen PY, Rahman
R.
Improved
survival among females and association with lymphopenia in
patients with newly diagnosed glioblastoma.
Neuro
Oncol. 2022 Aug 16, 2022:noac190∟.
doi: 10.1093/neuonc/noac190∟.
PMID: 35973053∟.
Letter to the Editor / Observational study. ˍ
*
Yang
G, Fang Y, Zhou M, Li W, Dong D, Chen J, Da Y, Wang K, Li X, Zhang
X, Ma T, Shen G.
Case
report: The effective response to pembrolizumab in combination
with bevacizumab in the treatment of a recurrent glioblastoma with
multiple extracranial metastases.
Front
Oncol. 2022 Aug 16;12:948933∟.
doi: 10.3389/fonc.2022.948933∟.
PMID: 36052225∟.
Case report. ˍ
Reinhardt
A, Pfister K, Schrimpf D, Stichel D, Sahm F, Reuss DE, Capper D,
Wefers AK, Ebrahimi A, Sill M, Felsberg J, Reifenberger G, Becker
A, Prinz M, Staszewski O, Hartmann C, Schittenhelm J, Gramatzki D,
Weller M, Olar A, Rushing EJ, Bergmann M, Farrell MA, Blümcke
I, Coras R, Beckervordersandforth J, Kim SH, Rogerio F, Dimova PS,
Niehusmann P, Unterberg A, Platten M, Pfister SM, Wick W,
Herold-Mende C, von Deimling A.
Anaplastic
ganglioglioma - a diagnosis comprising several distinct tumour
types.
Neuropathol
Appl Neurobiol. 2022 Aug 17, 2022:e12847∟.
doi: 10.1111/nan.12847∟.
PMID: 35977725∟.
Observational study. ˍ
Zhang
HH, Du XJ, Deng ML, Zheng L, Yao DC, Wang ZQ, Yang QY, Wu
SX.
Apatinib
for recurrent/progressive glioblastoma multiforme: A salvage
option.
Front
Pharmacol. 2022 Aug 17;13:969565∟.
doi: 10.3389/fphar.2022.969565∟.
PMID: 36060005∟.
Observational study. ˍ
Liu
APY, Dhanda SK, Lin T, Sioson E, Vasilyeva A, Gudenas B,
Tatevossian RG, Jia S, Neale G, Bowers DC, Hassall T, Partap S,
Crawford JR, Chintagumpala M, Bouffet E, McCowage G, Broniscer A,
Qaddoumi I, Armstrong G, Wright KD, Upadhyaya SA, Vinitsky A,
Tinkle CL, Lucas J, Chiang J, Indelicato DJ, Sanders R, Klimo P
Jr, Boop FA, Merchant TE, Ellison DW, Northcott PA, Orr BA, Zhou
X, Onar-Thomas A, Gajjar A, Robinson GW.
Molecular
classification and outcome of children with rare CNS embryonal
tumors: results from St. Jude Children's Research Hospital
including the multi-center SJYC07 and SJMB03 clinical trials.
Acta
Neuropathol. 2022 Aug 18∟.
doi: 10.1007/s00401-022-02484∟.
PMID: 35982322∟.
Observational study˰ ˍ
Milad S, Ehsan J, Seyed Farzad
M, Mohsen R, Ahmad B, Shahram M, Niayesh M, Alireza K.
Effects
of Dimethyl Fumarate on the Karnofsky Performance Status and Serum
S100β Level in Newly Glioblastoma Patients: A Randomized,
Phase-II, Placebo, Triple Blinded, Controlled Trial: Effect of DMF
On the Serum S100β Level and KPS Score of GBM Patients.
Galen
Med J. 2022 Aug 18;10:1-10∟.
doi: 10.31661/gmj.v11i.1897∟.
PMID: 36340958∟.
Interventional study. ˍ
Murk
K, Hülse R.
Forced
but effective partners in crime: How astrocytes drive the
progression of glioblastoma.
Brain.
2022 Aug 18, 2022:awac302∟.
doi: 10.1093/brain/awac302∟.
PMID: 35978482∟.
Comment. ˍ
Refers
to: Perelroizen
R et al., Astrocyte immunometabolic regulation of the tumour
microenvironment drives glioblastoma pathogenicity.
Brain.
2022 Jul 28, 2022:awac222∟.
doi: 10.1093/brain/awac222∟.
PMID: 35899587∟.
Laboratory investigation. ˍ
Simonelli
M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao
Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E,
Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL,
Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R,
Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N,
Ziti-Ljajic S, Massard C.
Isatuximab
plus atezolizumab in patients with advanced solid tumors: results
from a phase I/II, open-label, multicenter study.
ESMO
Open. 2022 Aug 18;7(5):100562∟.
doi: 10.1016/j.esmoop.2022.100562∟.
PMID: 35987165∟.
Interventional study. ˍ
Smaal
JA, Postma AA, Beckervordersandforth J, Anten M.
Primary
bone destruction and extracranial metastases in an atypical
glioblastoma with sarcomatoid features.
BMJ
Case Rep. 2022 Aug 18;15(8):e247248∟.
doi: 10.1136/bcr-2021-247248∟.
PMID: 35981750∟.
Case report˰ ˍ
Balkanov AS, Rozanov ID, Glazkov
AA.
Relationship
of carbohydrate metabolism indicators during adjuvant radiotherapy
and survival in patients with glioblastoma.
Zh
Vopr Neirokhir Im N N Burdenko. 2022 [Aug 19];86(5):13-20∟.
doi: 10.17116/neiro20228605113∟.
PMID: 36252189∟.
Observational study. ˍ
Costa
IN, Reis J, Pinheiro J, Silva R, Fernandes C.
Dabrafenib
Plus Trametinib: An Impressive Response in an Adult Patient With
BRAF V600E-Mutated and Isocitrate Dehydrogenase (IDH) Wild-Type
Glioma.
Cureus.
2022 Aug 19;14(8):e28156∟.
doi: 10.7759/cureus.28156∟.
PMID: 36158392∟.
Case report. ˍ
Fadel
HA, Haider S, Pawloski JA, Zakaria HM, Macki M, Bartlett S,
Schultz L, Robin AM, Kalkanis SN, Lee IY.
Laser
Interstitial Thermal Therapy for First-Line Treatment of
Surgically Accessible Recurrent Glioblastoma: Outcomes Compared
With a Surgical Cohort.
Neurosurgery.
2022 Aug 19∟.
doi: 10.1227/neu.0000000000002093∟.
PMID: 35986677∟.
Observational
study˰ ˍ
*
Wang
G, Guan S, Yang X, Sun S, Huang B, Li X.
Administration
of valproic acid improves the survival of patients with glioma
treated with postoperative radiotherapy.
Oncol
Res Treat. 2022 Aug 19∟.
doi: 10.1159/000526327∟.
PMID: 35988539∟.
Observational study˰ ˍ
Gregucci
F, Surgo A, Carbonara R, Laera L, Ciliberti MP, Gentile MA,
Caliandro M, Sasso N, Bonaparte I, Fanelli V, Tortora R,
Paulicelli E, Surico G, Lombardi G, Signorelli F, Fiorentino
A.
Radiosurgery
and Stereotactic Brain Radiotherapy with Systemic Therapy in
Recurrent High-Grade Gliomas: Is It Feasible? Therapeutic
Strategies in Recurrent High-Grade Gliomas.
J
Pers Med. 2022 Aug 20;12(8):1336∟.
doi: 10.3390/jpm12081336∟.
PMID: 36013284∟.
Observational study. ˍ
*
Szylberg
M, Sokal P, Śledzińska P, Bebyn M, Krajewski S, Szylberg
Ł, Szylberg A, Szylberg T, Krystkiewicz K, Birski M, Harat M,
Włodarski R, Furtak J.
MGMT
Promoter
Methylation as a Prognostic Factor in Primary Glioblastoma: A
Single-Institution Observational Study.
Biomedicines.
2022 Aug 20;10(8):2030∟.
doi: 10.3390/biomedicines10082030∟.
PMID: 36009577∟.
Observational study. ˍ
Upadhyay
R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J,
Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De
Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S,
Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI,
Johnson JM, McGovern SL.
Patterns
of failure after radiation therapy in primary spinal high-grade
gliomas: A single institutional analysis.
Neurooncol
Adv. 2022 Aug 20;4(1):vdac129∟.
doi: 10.1093/noajnl/vdac129∟.
PMID: 36128585∟.
Observational study. ˍ
Kim
M, Kim S, Park YW, Han K, Ahn SS, Moon JH, Kim EH, Kim J, Kang SG,
Chang JH, Kim SH, Lee SK.
Sex
as a prognostic factor in adult-type diffuse gliomas: an
integrated clinical and molecular analysis according to the 2021
WHO classification.
J
Neurooncol. 2022 Aug 21∟.
doi: 10.1007/s11060-022-04114-4∟.
PMID: 35988090∟.
Observational study˰ ˍ
Ostrom
QT, Shoaf ML, Cioffi G, Waite K, Kruchko C, Wen PY, Brat D,
Barnholtz-Sloan JS, Iorgulescu JB.
National-level
overall survival patterns for molecularly-defined diffuse glioma
types in the United States.
Neuro
Oncol. 2022 Aug 22, 2022:noac198∟.
doi: 10.1093/neuonc/noac198∟.
PMID: 35994777∟.
Observational study˰ ˍ
*
Şahin
M, Akgun E, Sirolu S, Can G, Sayman HB, Oner Dincbas F.
Is
there any additional benefit of 68Ga-PSMA
PET on Radiotherapy Target Volume Definition in Patients with
Glioblastoma?
Br
J Radiol. 2022 Aug 22, 2022:20220049∟.
doi: 10.1259/bjr.20220049∟.
PMID: 35993417∟.
Observational study˰ ˍ
Garcia
MR, Feng Y, Vasudevaraja V, Galbraith K, Serrano J, Thomas C,
Radmanesh A, Hidalgo ET, Harter DH, Allen JC, Gardner SL, Osorio
DS, William CM, Zagzag D, Boué DR, Snuderl M.
Clinical,
Pathological, and Molecular Characteristics of Diffuse Spinal Cord
Gliomas.
J
Neuropathol Exp Neurol. 2022 Aug 23, 2022:nlac075∟.
doi: 10.1093/jnen/nlac075∟.
PMID: 35997552∟.
Observational study˰ ˍ
Mair
MJ, Leibetseder A, Heller G, Puhr R, Tomasich E, Goldberger S,
Hatziioannou T, Woehrer A, Widhalm G, Dieckmann K, Aichholzer M,
Weis S, von Oertzen T, Furtner J, Pichler J, Preusser M, Berghoff
AS.
Early
postoperative treatment versus initial observation in CNS WHO
grade 2 and 3 oligodendroglioma: clinical outcomes and DNA
methylation patterns.
Clin
Cancer Res. 2022 Aug 23, 2022:CCR-22-1133∟.
doi: 10.1158/1078-0432.CCR-22-1133∟.
PMID: 35998208∟.
Observational study˰ ˍ
Wang
M, Zhang Y, Shi W, Zhu R, Li H, Zhao R.
Frameless
robot-assisted stereotactic biopsy: an effective and minimally
invasive technique for pediatric diffuse intrinsic pontine
gliomas.
J
Neurooncol. 2022 Aug 23∟.
doi: 10.1007/s11060-022-04122-4∟.
PMID: 35997920∟.
Observational study˰ ˍ
Deltour
I, Poulsen AH, Johansen C, Feychting M, Johannesen TB, Auvinen A,
Schüz J.
Time
trends in mobile phone use and glioma incidence among males in the
Nordic Countries, 1979-2016.
Environ
Int. 2022 Aug 24;168:107487∟.
doi: 10.1016/j.envint.2022.107487∟.
PMID: 36041243∟.
Observational study. ˍ
Garzio
K, McElroy K, Grossman S, Holdhoff M, Ozer B, Yankulina O.
Safety
of temozolomide use in adult patients with renal dysfunction.
J
Neurooncol. 2022 Aug 24∟.
doi: 10.1007/s11060-022-04098-1∟.
PMID: 36001203∟.
Observational study˰ ˍ
*
Lazaridis L, Bumes E, Cäcilia
Spille D, Schulz T, Heider S, Agkatsev S, Schmidt T, Blau T, Oster
C, Feldheim J, Stummer W, Kessler AF, Seidel C, Grauer O, Hau P,
Sure U, Keyvani K, Herrlinger U, Kleinschnitz C, Stuschke M,
Herrmann K, Deuschl C, Breuer S, Hattingen E, Scheffler B, Kebir
S, Glas M.
First
multicentric real-life experience with the combination of CCNU and
temozolomide in newly diagnosed MGMT
promoter
methylated IDH
wildtype
glioblastoma.
Neurooncol
Adv. 2022 Aug 24;4(1):vdac137∟.
doi: 10.1093/noajnl/vdac137∟.
PMID: 36284931∟.
Observational study. ˍ
Refers
to: Herrlinger
U, et al., Lomustine-temozolomide
combination therapy versus standard temozolomide therapy in
patients with newly diagnosed glioblastoma with methylated MGMT
promoter (CeTeG/NOA-09): a randomised, open-label, phase 3
trial.
Lancet.
2019 Feb 16, 2019;393(10172):678-688∟.
doi: 10.1016/S0140-6736(18)31791-4∟.
PMID: 30782343∟.
Interventional study. ˍ
Łysiak
M, Das J, Malmström A, Söderkvist P.
Methylation
associated with long- or short-term survival in glioblastoma
patients from the Nordic phase 3 trial.
Front
Genet. 2022 Aug 25;13:934519∟.
doi: 10.3389/fgene.2022.934519∟.
PMID: 36092918∟.
Observational study. ˍ
Mduma
E, Awuor A, Lugina EL.
Adult
medulloblastoma: a case report.
J
Med Case Rep. 2022 Aug 25;16(1):330∟.
doi: 10.1186/s13256-022-03531-3∟.
PMID: 36002876∟.
Case report. ˍ
*
Tzaridis
T, Weller J, Bachurski D, Shakeri F, Schaub C, Hau P, Buness A,
Schlegel U, Steinbach JP, Seidel C, Goldbrunner R, Schäfer N,
Wechsler-Reya RJ, Hallek M, Scheffler B, Glas M, Haeberle L,
Herrlinger U, Coch C, Reiners KS, Hartmann G.
A
novel serum extracellular vesicle protein signature to monitor
glioblastoma tumor progression.
Int
J Cancer. 2022 Aug 27∟.
doi: 10.1002/ijc.34261∟.
PMID:
36054558∟.
Laboratory investigation. ˍ
Kumar
TS, Afnan WM, Chan CY, Audrey C, Fong SL, Rajandram R, Lim KS,
Narayanan V.
Impact
of seizures and antiseizure medication on survival in patients
with glioma.
J
Neurooncol. 2022 Aug 29∟.
doi: 10.1007/s11060-022-04108-2∟.
PMID: 36036318∟.
Observational study˰ ˍ
Liz-Pimenta
J, Dias N, Barbosa M, Sousa M.
Priapism
Secondary to Low-Molecular-Weight Heparins: A Case Report.
Acta
Med Port. 2022 Aug 29∟.
doi: 10.20344/amp.18350∟.
PMID: 36036725∟.
Case report. ˍ
Shao
C, Tang H, Wang X, He J, Wang P, Wu N.
Body
mass index and glioma risk: A prospective multicenter study.
Front
Endocrinol (Lausanne). 2022 Aug 29;13:933921∟.
doi: 10.3389/fendo.2022.933921∟.
PMID: 36105407∟.
Observational study. ˍ
Zong
WF, Liu C, Zhang Y, Zhang SJ, Qu WS, Luo X.
Identification
of a Signature for Predicting Prognosis and Immunotherapy Response
in Patients with Glioma.
J
Oncol. 2022 Aug 29;2022:8615949∟.
doi: 10.1155/2022/8615949∟.
PMID: 36072978∟.
Laboratory investigation. ˍ
Han
D, Teng L, Wang X, Zhen Y, Chen X, Yang M, Gao M, Yang G, Han M,
Wang L, Xu J, Li Y, Shumadalova A, Zhao S.
Phase
I/II trial of local interstitial chemotherapy with arsenic
trioxide in patients with newly diagnosed glioma.
Front
Neurol. 2022 Aug 30;13:1001829∟.
doi: 10.3389/fneur.2022.1001829∟.
PMID: 36212657∟.
Interventional study. ˍ
Ioakeim-Ioannidou
M, Giantsoudi D, Niemierko A, Sethi R, Kim DW, Yock TI, Tarbell
NJ, Simeone FJ, MacDonald SM.
Effects
of Proton Craniospinal Radiation on Vertebral Body Growth
Retardation in Children.
Int
J Radiat Oncol Biol Phys. 2022 Aug 30,
2022:S0360-3016(22)03212-6∟.
doi: 10.1016/j.ijrobp.2022.08.055∟.
PMID: 36055432∟.
Observational study. ˍ
*
Ohno
M, Kitanaka C, Miyakita Y, Tanaka S, Sonoda Y, Mishima K, Ishikawa
E, Takahashi M, Yanagisawa S, Ohashi K, Nagane M, Narita
Y.
Metformin
with Temozolomide for Newly Diagnosed Glioblastoma: Results of
Phase I Study and a Brief Review of Relevant Studies.
Cancers
(Basel). 2022 Aug 30;14(17):4222∟.
doi: 10.3390/cancers14174222∟.
PMID: 36077758∟.
Interventional study and Review. ˍ
Le
HT, Staelens M, Lazzari D, Chan G, Tuszyński JA.
Real-Time
Monitoring of the Effect of Tumour-Treating Fields on Cell
Division Using Live-Cell Imaging.
Cells.
2022 Aug 31;11(17):2712∟.
doi: 10.3390/cells11172712∟.
PMID: 36078119∟.
Laboratory investigation. ˍ
*
Rodríguez-Morales
J, Guartazaca-Guerrero S, Rizo-Téllez SA, Viurcos-Sanabria
R, Barrón EV, Hernández-Valencia AF, Nava P,
Escobedo G, Carrillo-Ruiz JD, Méndez-García
LA.
Blood-brain
Barrier Damage is Pivotal for SARS-CoV-2 Infection to the Central
Nervous System.
Exp
Neurobiol. 2022 Aug 31;31(4):270-276∟.
doi: 10.5607/en21049∟.
PMID: 36050226∟.
Case report. ˍ